

**From:** Wendy McGuinness <[wmcg@mcguinnessinstitute.org](mailto:wmcg@mcguinnessinstitute.org)>  
**Date:** Thursday, 23 July 2020 at 4:51 PM  
**To:** "[Edie.Taylor@health.govt.nz](mailto:Edie.Taylor@health.govt.nz)" <[Edie.Taylor@health.govt.nz](mailto:Edie.Taylor@health.govt.nz)>, "[oiagr@health.govt.nz](mailto:oiagr@health.govt.nz)" <[oiagr@health.govt.nz](mailto:oiagr@health.govt.nz)>  
**Cc:** Reuben Staff <[rb@mcguinnessinstitute.org](mailto:rb@mcguinnessinstitute.org)>  
**Subject:** Follow on request for further information in response to OIA (ref: H202002574)

Good afternoon,

Please treat this email as a request for information under the OIA.

Below are a series of questions regarding personal protective equipment (PPE) procurement and the National Reserve Supply (NRS). These questions follow on from OIA (ref no. H202002574, attached), which was a response to an earlier OIA we sent on 20 April 2020. As the severity of the pandemic escalates overseas, the case of a second wave outbreak is increasingly likely (e.g. Melbourne). We want to ensure that New Zealand has a robust strategy in place for the procurement of PPE so that it is available, accessible and managed efficiently if required.

The following questions relate to a series of logistical issues:

1. Can you advise when the MoH [webpage](#) that records the composition of the NRS will be updated? Your response to the previous OIA stated that 'the page on National Reserve Supply (NRS) is being reviewed and will be updated by the end of May 2020'. Furthermore, can you explain why this has been delayed?
2. Are there any standards and/or regulations in place for those purchasing and/or manufacturing PPE in New Zealand? If applicable, please direct us to the standards and/or regulations for PPE that have been adopted when procuring PPE? In addition, are DHBs and the MoH required to meet these standards when procuring PPE?
3. In addition to PPE, are there standards for the contents of hand sanitiser? We have been advised there are products currently on the market that are listed as having antibacterial properties, but do not contain the necessary chemicals to destroy the coronavirus.
4. If there are standards, has an audit been undertaken of all existing inventory against those standards for inventory held (i) by the MoH and (ii) by each DHB? If yes, can you please provide a copy of the audit results? If no, can you advise why this was not deemed necessary?
5. Please advise whether there is an updated pandemic plan, or whether the government is looking to update the 2017 [New Zealand Influenza Pandemic Plan A framework for action](#)?

6. Can we please have a breakdown of PPE purchased by MoH from New Zealand manufacturers by (i) type of PPE and (ii) name of manufacturer since January 2020 to 30 July 2020?
7. What amount and type of PPE was acquired by the MoH from the group mentioned in this article(see link [here](#)) (i.e. Graeme Hart, Sir Stephen Tindall, Craig Heatley, Nick Mowbray and Sam Morgan)? Can you also provide the costs and timing of the procurement? Lastly, can you please confirm whether the PPE was acquired at cost from overseas sources (as specified in the article linked above)?

If possible, please provide any links to reports or other sources used to answer the above questions. Thank you again for your help.

Kind regards,

Wendy

## McGuinness Institute Te Hononga Waka

Level 2, 5 Cable Street, Wellington 6011 | PO Box 24-222 Wellington 6142  
+64 4 499 8888 | [www.mcguinnessinstitute.org](http://www.mcguinnessinstitute.org)

The McGuinness Institute is a non-partisan think tank working towards a sustainable future, contributing strategic foresight through evidence-based research and policy analysis.

Disclaimer: This email is intended only to be read or used by the addressee. It is confidential and may contain legally privileged information. If you are not the addressee indicated in this message (or responsible for delivery of the message to such person), you may not copy or deliver this message to anyone, and you should destroy this message and kindly notify the sender by reply email. Confidentiality and legal privilege are not waived or lost by reason of mistaken delivery to you.

**From:** <[Edie.Taylor@health.govt.nz](mailto:Edie.Taylor@health.govt.nz)> on behalf of "[oiagr@health.govt.nz](mailto:oiagr@health.govt.nz)" <[oiagr@health.govt.nz](mailto:oiagr@health.govt.nz)>

**Date:** Thursday, 21 May 2020 at 17:25

**To:** Wendy McGuinness <[wmcg@mcguinnessinstitute.org](mailto:wmcg@mcguinnessinstitute.org)>

**Cc:** "[oiagr@health.govt.nz](mailto:oiagr@health.govt.nz)" <[oiagr@health.govt.nz](mailto:oiagr@health.govt.nz)>

**Subject:** Response to request for official information (ref: H202002574)

Kia ora Ms McGuinness

Please find attached a letter regarding your request for information.

Ngā mihi

### OIA Services

Government Services

Office of the Director-General

Ministry of Health

E: [oiagr@health.govt.nz](mailto:oiagr@health.govt.nz)



\*\*\*\*\*

Statement of confidentiality: This e-mail message and any accompanying attachments may contain information that is IN-CONFIDENCE and subject to legal privilege.

If you are not the intended recipient, do not read, use, disseminate, distribute or copy this message or attachments.

If you have received this message in error, please notify the sender immediately and delete this message.

\*\*\*\*\*

---

This e-mail message has been scanned for Viruses and Content and cleared by the Ministry of Health's Content and Virus Filtering Gateway